Literature DB >> 14557434

Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone.

Gérard Maruani1, Alexandre Hertig, Michel Paillard, Pascal Houillier.   

Abstract

Primary hyperparathyroidism (PHPT) is usually characterized by fasting hypercalcemia associated with inappropriately high PTH concentration. Nevertheless, cases of proven PHPT have been reported in normocalcemic patients. The purpose of the study was to investigate the mechanism(s) of persistent normocalcemia in PHPT. One hundred seventy-eight patients with PHPT were studied after exclusion of any evident cause of masked hypercalcemia. Patients were separated into normocalcemic (n = 34) and hypercalcemic (n = 144) subgroups on the basis of their fasting serum ionized calcium value. Patients with normocalcemic PHPT had, on average, a milder excess in PTH secretion assessed by a lower serum PTH concentration. Because of a clear overlap in PTH values between the two groups, normocalcemic and hypercalcemic patients were matched on the basis of serum PTH concentration, age, and sex. Patients with normocalcemic PHPT had lower fasting urine calcium excretion and renal tubular calcium reabsorption. In addition, normocalcemic patients differed from hypercalcemic patients by lower values of markers of bone turnover and plasma 1,25 dihydroxyvitamin D and higher values of renal phosphate threshold. In conclusion, a significant proportion of patients with PHPT are truly normocalcemic, and in addition to a milder increase in PTH secretion, the normocalcemic patients appear to display resistance to PTH action on bone and kidney.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557434     DOI: 10.1210/jc.2002-021404

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Authors:  Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam
Journal:  Bone       Date:  2010-05-13       Impact factor: 4.398

Review 2.  Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism.

Authors:  J C Souberbielle; P Boudou; C Cormier
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

Review 3.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

4.  Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?

Authors:  Thyciara Fontenele Marques; Renata Vasconcelos; Erik Diniz; Daniela Rêgo; Luiz Griz; Francisco Bandeira
Journal:  Arq Bras Endocrinol Metabol       Date:  2011-06

5.  Diagnosis and clinico-radiological presentation in an aggressive maxillary brown tumour.

Authors:  Abhishek Ranjan Pati; Vijayalakshmi Kr; Chandravir Singh
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 6.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 7.  Normocalcemic primary hyperparathyroidism.

Authors:  John P Bilezikian; Shonni J Silverberg
Journal:  Arq Bras Endocrinol Metabol       Date:  2010-03

Review 8.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

9.  Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors:  Emanuela Traini; Rocco Bellantone; Serena Elisa Tempera; Salvatore Russo; Carmela De Crea; Celestino Pio Lombardi; Marco Raffaelli
Journal:  Langenbecks Arch Surg       Date:  2018-03-14       Impact factor: 3.445

10.  PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.

Authors:  Alexandre Loupy; Suresh Krishna Ramakrishnan; Bharath Wootla; Régine Chambrey; Renaud de la Faille; Soline Bourgeois; Patrick Bruneval; Chantal Mandet; Erik Ilso Christensen; Hélène Faure; Lydie Cheval; Kamel Laghmani; Corinne Collet; Dominique Eladari; Robert H Dodd; Martial Ruat; Pascal Houillier
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.